Company profile

Tubulis GmbH

Privately held: no public share price (Acquired outright by Gilead Sciences, deal closed 21 May 2026; now a wholly-owned subsidiary with no independent equity. Parent: Gilead Sciences, Inc. (Nasdaq: GILD). [resolved 2026-08-05 by resolve-null-is-public; source: https://www.gilead.com/news/news-details/2026/gilead-sciences-completes-acquisition-of-tubulis-further-strengthening-oncology-portfolio]) · Germany

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
TUB-030
Phase 2
5T4 (trophoblast glycoprotein, TPBG)Small molecule
Non-Small Cell Lung Cancer
TUB-040
Phase 2
NaPi2b (sodium-dependent phosphate transporter, SLC34A2)Small molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Educational data tool. Figures are sourced from company filings and press releases: see each row's filing link. Share price is delayed (~15min) and refreshed periodically, not a real-time feed.